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Selective CREB-dependent cyclin expression mediated by the
PI3K and MAPK pathways supports glioma cell proliferation
P Daniel1, G Filiz1, DV Brown1, F Hollande1, M Gonzales1,2, G D’Abaco3, N Papalexis4, WA Phillips5,6, J Malaterre6,7, RG Ramsay6,7
and T Mantamadiotis1,4
The cyclic-AMP response element binding (CREB) protein has been shown to have a pivotal role in cell survival and cell proliferation.
Transgenic rodent models have revealed a role for CREB in higher-order brain functions, such as memory and drug addiction
behaviors. CREB overexpression in transgenic animals imparts oncogenic properties on cells in various tissues, and aberrant CREB
expression is associated with tumours. It is the central position of CREB, downstream from key developmental and growth
signalling pathways, which gives CREB this ability to inﬂuence a spectrum of cellular activities, such as cell survival, growth and
differentiation, in both normal and cancer cells. We show that CREB is highly expressed and constitutively activated in patient
glioma tissue and that this activation closely correlates with tumour grade. The mechanism by which CREB regulates glioblastoma
(GBM) tumour cell proliferation involves activities downstream from both the mitogen-activated protein kinase and
phosphoinositide 3-kinase (PI3K) pathways that then modulate the expression of three key cell cycle factors, cyclin B, D and
proliferating cell nuclear antigen (PCNA). Cyclin D1 is highly CREB-dependent, whereas cyclin B1 and PCNA are co-regulated by
both CREB-dependent and -independent mechanisms. The precise regulatory network involved appears to differ depending on the
tumour-suppressor phosphatase and tensin homolog status of the GBM cells, which in turn allows CREB to regulate the activity of
the PI3K itself. Given that CREB sits at the hub of key cancer cell signalling pathways, understanding the role of glioma-speciﬁc CREB
function may lead to improved novel combinatorial anti-tumour therapies, which can complement existing PI3K-speciﬁc drugs
undergoing early phase clinical trials.
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INTRODUCTION
Patients diagnosed with malignant glioblastoma (GBM) show a
median survival of 14 months; a statistic largely unchanged over
the past decades. For gliomas, the only drug used as part of the
standard therapy is the DNA alkylating/methylating agent
temozolomide, which has led to an improvement in median
overall survival, ranging between 0 and 7 months, depending on
the methylation status of the patient’s DNA repair gene, MGMT.1
Attempts at targeting speciﬁc factors in GBM have so far
been unsuccessful, with such attempts exempliﬁed by clinical
trials conducted recently: the use of the promising angiogenesis
inhibitor bevacizumab (Avastin)2 or a combination of
bevacizumab and a phosphoinositide 3-kinase (PI3K) pathway
inhibitor provided no beneﬁt to patients.3 Therefore there is a
need to develop better approaches for treating gliomas to
improve patient survival. To progress the discovery and testing
of novel drugs and combinations of drugs, the understanding of
the molecular genetic mechanisms and factors driving GBM
development, growth and drug resistance must be clariﬁed.
Among the factors and pathways implicated in glioma
development and growth, the kinases PI3K and mitogen-
activated protein kinase (MAPK) are among the most studied.
Highlighting the critical role of these kinases in cancer, 480% of
GBM patients harbour alterations such as epidermal growth factor
receptor (EGFR) ampliﬁcation, EGFRvIII-activating mutation
and/or downstream PIK3CA-activating mutations or phosphatase
and tensin homolog (PTEN) deletions,4 contributing to the
hyperactivation of the downstream effectors such as
extracellular signal–regulated kinase and AKT, key drivers of
pathogenesis in GBM.5 Although aspects of the immediate
upstream and downstream components of these pathways are
relatively well understood, the feedback loops and nuclear target
networks controlling these pathways in GBM biology are not as
well deﬁned.
As many cancer signalling pathways converge on nuclear
transcription factors, which then orchestrate the expression of a
tumour-promoting transcriptome, targeting these transcription
factors in combination with upstream-activating factors may be an
attractive approach. Indeed, this has come to the fore in terms of
emerging anti-tumour strategies6–9 In cancer cells, one of the
transcription factors that sit at the hub of tumour cell signalling
pathways is the cyclic-AMP response element binding (CREB)
protein, a serine/threonine kinase-regulated transcription factor in
which phosphorylation of CREB in the N-terminal kinase-inducible
domain recruits transcriptional co-activators such as CREB-binding
protein and transducers of regulated CREB activity to activate
CREB target gene transcription.10,11 CREB has been implicated in
the growth and progression of multiple cancers, including
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leukemia,12,13 colorectal cancer14 and breast cancer.15 CREB lies at
the hub of multiple oncogenic signalling pathways initiated by
ligand-growth factor receptor interactions such as the platelet-
derived growth factor receptor and EGFR receptor tyrosine kinases
and is activated by numerous downstream kinase pathways,
including PI3K and MAPK, and deactivated by tumour suppressors,
including PTEN. In melanoma cells harbouring BRAF(V600E)
mutations, CREB is a key factor involved in MAPK pathway-
mediated drug resistance16 In GBM, CREB function appears to
regulate growth of tumour cells via transcriptional control of
miRNA-23a17 and Nf-1.18 Previous work has shown that loss of
CREB function during brain development leads to neuronal
death19,20 and that CREB is required for efﬁcient neuronal stem
and progenitor cell proliferation21,22 Based on these ﬁndings, we
hypothesized that CREB activation is a critical step in
gliomagenesis and that CREB function sits downstream of key
cancer signalling pathways.
We show that CREB expression and activation correlates with
glioma grade and that activation occurs via both the PI3K and
MAPK pathways and that CREB promotes glioma cell proliferation.
Furthermore, we show that the mechanism by which CREB
promotes glioma cell proliferation includes the regulation of key
cell cycle factors cyclin B1, D1 and proliferating cell nuclear
antigen (PCNA).
RESULTS
CREB is constitutively activated in human GBM cells lines and
human brain tumours exhibit grade-dependent pCREB expression
Although CREB is expressed throughout the normal brain during
all stages of life, constitutively phosphorylated CREB (pCREB) is
progressively restricted to neurogenic zones. It is within these
zones that neural stem/progenitor cell (NSPC) populations reside
and CREB gene/expression disruption studies in mice and
zebraﬁsh show that NSPC proliferation and survival depends on
CREB function.21,22 Based on data showing that CREB has
oncogenic roles in the hemopoietic system12 and other tissues23
and as the CREB functions required by NSPCs may be important in
GBM biology, we explored CREB expression, activation and
function in brain tumour tissue and cells. Assessment of CREB
expression and activation in human GBM tumour cell lines using
CREB and pCREB antibodies revealed that GBM tumour lines
showed robust CREB and pCREB expression. Non-tumour brain
tissue exhibited weaker total CREB expression and undetectable
levels of pCREB (Figure 1a).
Using whole GBM surgical tumour specimens prepared from
formalin-ﬁxed, parafﬁn-embedded tissue, we examined the mor-
phological landscape of a further 15 patient specimens diagnosed
with grade IV GBM. GBM tumour morphologies associated with
pCREB expression are shown in Figures 1b-i–vi. pCREB expression
was evident in most tumour cells examined with a clustering of
strong pCREB expression in highly vascularized tumour regions
(Figure 1b-i) and in regions with strong nestin expression
(Figure 1b-vi). pCREB-positive cell density and expression was high
in hypercellular pseudopalisading regions adjacent to necrotic
regions, where migrating proliferating tumour cells are seen
(Figure 1b-iii, arrows). Of note, tumour morphologies corresponding
to GBM regions associated with less malignant characteristics
exhibited weaker pCREB expression. Giant cells in GBM showed
relatively weaker pCREB expression (Figure 1b-ii, arrows), and cells
in tumour regions with oligodendroglial features, characterized by
the so-called ‘chicken wire’ or ‘fried egg’ morphology showed the
weakest pCREB expression (Figures 1b-iv and -v, arrows).
Interrogation of glioma tissue microarray specimens harbouring
40 patient glioma tissue cores (3mm diameter) in duplicate
showed that while ‘normal’ non-tumour and ‘normal tissue
adjacent to tumour’ showed little-to-no CREB activation. By
contrast, tumour tissue exhibited robust grade-dependent levels
of pCREB expression (Figure 1c). Grade II tumours showed the
lowest levels of pCREB, and WHO grade IV tissues exhibited the
strongest pCREB positivity. Both pCREB intensity and the number
of cells expressing pCREB correlated with tumour grade, where
grade IV GBM showed the most intense and highest density of
pCREB-positive cells. Using a ‘þ ’ scale where ‘þ ’ is just detectable
staining/1% to o5% of cell/ﬁeld positive and ‘þ þ þ þ þ ’ is
strong dark staining/almost 100% cells/ﬁeld positive, grade II
tumours showed between zero and ‘þ þ ’; grade III tumours
showed between ‘þ ’ and ‘þ þ þ ’ and grade IV/GBM showed
between ‘þ þ þ ’ and ‘þ þ þ þ þ ’. Three oligodendroglioma
specimens showed ‘þ ’, ‘þ ’ and ‘þ þ ’, while all ‘adjacent to
tumour’ and ‘normal’ brain tissue showed zero staining.
Using the GBM cell line T98G to examine CREB activation, we
show that pCREB coincides with cells in cycle. Speciﬁcally, pCREB is
present in cells undergoing S-phase of the cell cycle as shown by
co-labelling with PCNA and newly divided cells labelled with the
Figure 1. CREB is hyperactivated in glioma cell lines and tissue.
(a) Cells from a range of human glioma cell lines were lysed and
analysed from CREB expression and activation. All GBM cell lines
tested showed an abundance of CREB protein, which was
phosphorylated/activated. Non-tumour mouse brain tissue shows
expression of CREB but no detectable pCREB. (b) Immunohisto-
chemical analysis of human GBM tissue specimens show differential
pCREB expression. (i) pCREB-positive tumour cells surround a
tumour blood vessel; (ii) Giant cells in GBM show moderate-to-
strong pCREB labelling; (iii) pseudopalidaing areas (arrows) in GBM
show dense pCREB-positive tumour cells; (iv) and (v) two different
patient tumours featuring oligodendroglial features show weak
pCREB expression (arrows indicate oligodendroglial tumour cells);
and (vi) double-labelling immunohistochemistry showed dense
pCREB-positive cells (brown) surrounding foci with strong nestin
expression (blue). (c) Brain tumour tissue microarray (US Biomax)
with pCREB immunostaining. Top image shows the complete array
with tumour grade layout indicated and cores magnified in the
lower panel.
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nucleotide analogue bromodeoxyuridine (BrdU; Figure 2). In
contrast, cells labelled with the M-phase marker phospho-histone
3 (pH3) demonstrated poor colocalization to pCREB-positive cells.
PI3K and MAPK but not protein kinase A (PKA) signalling pathways
modulate CREB activity in GBM cells
Many signalling pathways relevant to GBM converge onto CREB,
suggesting that constitutive CREB activation as observed in GBM is
the result of cooperation between multiple upstream factors. To
determine which pathways activate CREB, we evaluated cells
grown in stimulatory and non-stimulatory conditions for differ-
ences in kinase activation. Several serine/threonine kinases that
are known to phosphorylate CREB at Serine133 were investigated.
Analysis of cell lines T98G, LN18 and U118 demonstrated
activation of CREB, AKT and MAPK upon serum stimulation. By
contrast, we did not observe activation of PKA, an activator of
CREB in other cell types (Figure 3a), showing that there is a
selective use of upstream components regulating CREB activity.
To link the speciﬁcity of AKT and MAPK activation with CREB
activation, the PI3K pathway inhibitor LY294002 and the MAPK
pathway inhibitor U0126 were used on T98G and U118 (Figures 3b
and c). These cell lines were chosen for further analysis for two
reasons. First, they showed the greatest CREB-dependent change
in proliferation (Figures 4b and c), and second, these cell lines
differ in the tumour-suppressor PTEN status, where T98G has
intact PTEN function and U118 is PTEN deﬁcient. One of the PTEN’s
major functions is to act as the major phosphatase that inhibits
the activation of the PI3K pathway24 Signiﬁcant variability was
seen between the cell lines tested with respect to the contribution
of either the PI3K or MAPK pathways on CREB activation. In U118
cells, inhibition of the PI3K pathway resulted in no change in CREB
activation, while inhibition of the MAPK pathway resulted in
knockdown of CREB activation to basal ‘serum-deprived’ levels,
suggesting that MAPK signalling is the predominant CREB
activation pathway in U118 cells (Figures 3c and e). By contrast,
inhibition of either or both the PI3K or MAPK pathways in T98G
cells did not result in signiﬁcant changes in CREB activation
(Figures 3b and d), highlighting the diversity and complex
interdependence between signalling pathways involved in CREB
activation in GBM cells.
As a further and independent measure of the contribution of
the PI3K pathway to CREB activation, we used a mutant NSPC that
has a constitutively activated PI3K pathway, due to the combined
conditional mutation of the Pik3ca gene, which encodes for the
major catalytic p110alpha subunit of PI3K, and has a conditional
loss of tumour-suppressor PTEN. These NSPCs were derived from a
conditional mutant mouse shown to develop tumours in various
tissues tested.25–27 CREB activation (pCREB) was signiﬁcantly
elevated along with AKT activation (pAKT), compared with
parental NSPCs from the same mouse in which the PI3K
pathway mutations were not activated (Figure 3f).
CREB function contributes to GBM cell proliferation
As CREB is strongly associated with proliferative zones within the
normal adult brain, we examined the effect of CREB knockdown
on GBM cell proliferation. We tested siRNA-mediated CREB
knockdown in ﬁve human GBM cell lines (T98G, U118, U373,
ANGM-CSS, U87), which represent cells with an array of GBM-
associated genetic alterations. The combined use of three CREB
siRNAs targeting different mRNA regions allowed robust CREB
expression knockdown (490%) over at least 120 h (Figure 4a) in
T98G cells. All ﬁve cell lines tested showed a reduction in cell
proliferation (n¼ 1, not shown). Further experiments were
performed with selected cell lines as indicated. The greatest
reduction in proliferation was seen in cell lines T98G and U118,
with a 58% and 52% reduction compared with scrambled siRNA-
transfected controls after 120 h (Figures 4b and c). As we have
Figure 2. CREB is activated in dividing cells. T98G cells
were analysed for the colocalization of pCREB(Ser 133) with
markers of cell proliferation: (a) PCNA, (b) phospho-histone (pH3),
nd (c) BrdU.
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Figure 3. The PI3K and MAPK-dependent signalling pathways but not the PKA pathway activate nuclear CREB in glioma cells. (a) GBM cell lines
T98G, LN18 and U118 were serum starved for 24 h then exposed to serum and protein lysate immunoblotted for the indicated antibodies.
(b, c) GBM cell lines T98G and U118 were pretreated with a PI3K inhibitor LY294002, a MAPK inhibitor U0126 or both inhibitors, and then
exposed to serum, protein lysate collected after 4 h and analysed for the presence of the indicated antibodies (d, e) Quantification of the
effects of inhibitor combinations on pCREB levels in T98G and U118 GBM cells. *Po0.05, **Po0.005. (f ) Western blotting showing the level of
pCREB and pAKT in mouse NSPCs grown as neurospheres, with an activated Pik3caH1047R mutation and PTEN deletion (M) or parental NSPCs
with ‘wild-type’ Pik3ca and PTEN (C). All western blottings were performed at least three times, and where applicable, total CREB, AKT and
MAPK were imaged, then membranes were stripped and reprobed for pCREB, pAKT and pMAPK detection.
Figure 4. CREB is required for efficient human glioma cell line proliferation. (a) T98G cells were transfected with either CREB1-specific siRNA
(siCREB) or scramble siRNA and then lysate analysed by western blotting for efficiency of CREB knockdown. *P¼ 0.05, **P¼ 0.005,
***P¼ 0.0005. (b, c) Scrambled or siCREB was transfected into GBM cell lines T98G and U118, and proliferation was analysed every 24 h using
an MTT assay. (d, e) Scrambled or siCREB was transfected into GBM cell lines T98G and U118, and apoptosis was determined by FACs
determination of AnnexinV uptake.
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previously shown that loss of CREB function in zebraﬁsh and
mouse brain as well as mouse neural NSPCs leads to compromized
cell survival, we tested whether this was the case in GBM cells.
Notably, cell survival was not affected by CREB knockdown using
two different assay systems, measuring lactate dehydrogenase
released from dead cells and measuring early apoptosis by
measuring appearance and accumulation of Annexin V (Figures 4d
and e) following CREB knockdown. Thus reduced cell numbers can
be attributed to reduced proliferation.
CREB knockdown leads to aberrant GBM cell cycle kinetics due to
inhibition of cell cycle factor expression
To determine the mechanism by which CREB regulates GBM cell
proliferation, cell cycle parameters were measured using DNA
content by ﬂow cytometry in T98G and U118 cells, which were the
cell lines showing the greatest CREB-dependent decrease in
proliferation. CREB knockdown increased the proportion of cells in
G0/G1 phase in both cell lines tested (Figures 5a and b). siCREB
T98G cells also showed signiﬁcantly reduced proportions in cell
cycle phase distribution in S- and G2/M phases compared with
control cells, whereas siCREB U118 cells exhibited increased G0/G1
and fewer G2/M phase cells only. To explore the molecular basis
underlying disruption of the cell cycle, we measured the expression
of cell cycle/proliferation factors previously reported to be
transcriptionally regulated by CREB, including cyclins B1, D128 and
PCNA.14,29 Protein expression of cyclins B1, D1 and PCNA was
assessed in T98G and U118 cells in CREB knockdown or scrambled
control siRNA-treated GBM cell lines (Figures 5c and d). Cells were
serum deprived for 24h before the addition of serum to synchronize
cell cycle activation, and cyclin and PCNA protein levels were
determined every 12h, over 48h. The dynamics of expression seen
was consistent with the reported cyclin and PCNA expression
proﬁles for mammalian cells, where PCNA and cyclin D1 are
consistently expressed throughout the cell cycle while cyclin B1
expression peaks at G2/M.30 Upon treatment with serum (triggering
cell cycle entry), we observed inhibition of protein expression of
cyclin B1, cyclin D1 and PCNA in both T98G and U118 cell lines as
early as 12h (not shown) with maximal inhibition reached at 24h,
compared with no-serum cells (Figures 5c and d). T98G cells showed
a consistent and almost complete block in cyclin D1, cyclin B1 and
PCNA expression over 48h in CREB knockdown cells, in contrast to
U118 cells, which exhibited a more modest inhibition of cyclin D1,
over 48h. In U118 cells, cylin B1 protein expression was maximally
inhibited at 24h, but little effect was seen in PCNA expression
(Figure 5d). Moreover, in U118 cells cyclin B1 inhibition was not
sustained, with expression approaching control levels beyond 24h.
Given that cyclin B1, D1 and PCNA harbour cAMP-resonsive
elements (CREB-binding sequences) in their promoters (see
Supplementary Data), we tested whether CREB exerted its inﬂuence
on these target genes directly; we performed reverse transcriptase–
PCR (RT–PCR) at 24h following siCREB treatment to measure mRNA
levels of cyclin B1, D1 and PCNA. CREB knockdown robustly
inhibited cyclin D1 mRNA expression in both T98G and U118
cells, while cyclin B1 mRNA expression was signiﬁcantly reduced in
T98G cells only. Surprisingly, PCNA mRNA expression was unaf-
fected by CREB knockdown in both cell lines (Figures 5e and f),
implying that CREB exerts its affect on PCNA protein expression
indirectly. The transcriptional inﬂuence CREB exerts in the expres-
sion of these genes reﬂects the context of the cAMP-resonsive
elements in their respective promoters (see Supplementary Data),
with cyclin D1 showing the best context with a full (8-base pair
consensus) cAMP-resonsive element positioned closest to the
transcription start site.
Figure 5. Knockdown of CREB alters human GBM cell cycle kinetics through regulation of cyclin B1, cyclin D1 and PCNA. (a, b) Synchronized
GBM cell lines T98G and U118 were treated with either siCREB or scramble control siRNA and then stimulated with serum for 24 h before
being analysed for cell cycle proportions using DNA-content analysis. (c, d) Synchronized GBM cell lines T98G and U118 were treated with
either siCREB or scramble control siRNA, stimulated with serum and harvested every 12 h for analysis for cyclin B1, cyclin D1 and PCNA
expression. (e, f ) Synchronized GBM cell lines T98G and U118 were treated with either siCREB or scrambled control siRNA and then stimulated
with serum for 24 h before harvesting and analysis using qRT–PCR for CCNB1, CCND1 and PCNA mRNA expression. ***Po0.0005, **Po0.005,
*Po0.05. All western blottings were performed at least three times, and blottings for total CREB assay were imaged, then membranes were
stripped and reprobed for pCREB detection.
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Selective CREB regulation of cell cycle factors by canonical and
non-canonical interations with the PI3K pathway
To investigate the mechanism of the differential regulation of
cyclin D1, cyclin B1 and PCNA by CREB in T98G compared with
U118 cells, we looked at whether CREB knockdown affected
upstream signalling components, given that previous studies have
shown a link between CREB and upstream signalling components
of the PI3K and MAPK pathways, such as insulin growth factor
receptor (IGFR) and insulin receptor substrate-1/2 (IRS-1/2).31,32
Crucially, T98G and U118 differ in PTEN status (T98G PTENþ and
U118 PTEN ), which may account for the differential CREB-
mediated regulation of cell cycle factors via interaction with the
MAPK and PI3K pathways.33,34 Treatment of T98G cells with siCREB
resulted in an almost complete block of AKT activation, which was
not rescued by the addition of serum (Figure 6a). In comparison,
CREB knockdown in U118 cells showed reduced AKT activation
only in serum-free conditions (Figure 6b). Upon the addition of
serum, AKT activation in U118 cells increased to levels identical to
control cells (Figure 6b).
To determine whether the cell-speciﬁc regulation of cyclin B1
and PCNA by CREB could be due to effects on AKT activation and/
or PTEN status, we used the PI3K inhibitor LY294002 in conjuction
with siCREB in U118 cells (Figure 6c). This experiment conﬁrmed
the dependence of cyclin D1 expression on CREB, with siCREB
treatment alone showing almost complete attenuation of cyclin
D1 expression. Furthermore, the expression of cyclin B1 and PCNA
were found to be dependent on both CREB and PI3K signalling.
Neither siCREB nor the PI3K inhibitor LY294002 alone could block
cyclin B1 or PCNA expression in U118 cells.
DISCUSSION
CREB-dependent brain functions have been extensively explored
with most previous studies focussed on neurological functions
ranging from learning and memory,35 opiate withdrawal36 to
feeding behavior.37 Other work has shown that CREB is critical for
neuronal survival and that CREB disruption in vivo leads to a
neurodegenerative phenotype20 and reduction in neural stem cell
survival and proliferation21,22 In parallel, a body of evidence has
accumulated showing that CREB imparts oncogenic properties on
cells outside the central nervous system.23,38 We focussed our
investigations on deﬁning CREB-dependent mechanisms
orchestrating malignant GBM cell proliferation. Analysis of a
panel of human GBM cell lines shows that CREB is not only highly
expressed but also constitutively hyperactivated (Figure 1a). This is
in contrast to non-tumour brain tissue, which show highly
regulated and transient activation, dependent on external
stimuli.11 Cells in adult mouse brain showing robust constitutive
phosphorylated CREB expression are enriched in the neurogenic
zones,22,39 so the constitutive expression of pCREB in GBM tumour
cells is consistent with the generally held view that tumour cells
exhibit immature stem/progenitor cell-like characteristics. In GBM
tissue examined, pCREB was evident in many GBM hallmark
morphological features, including near tumour angiogenic regions
(Figure 1b-i), peripheral to necrotic foci characterized by
pseudopalisading regions (Figure 1b-iii). This is interesting as
GBM regions with pseudopalisading features harbour migrating
tumour cells adjacent to hypoxic necrotic regions with high levels
of pro-angiogenic factors, including hypoxia-inducible factor-1,
vascular endothelial growth factor and interleukin-8, which are all
CREB target genes.40–42 CREB may therefore be intimately
involved in regulating the angiogenic tumour niche in GBM. In
one GBM tumour examined, strong pCREB-positive cells were
clustered in foci exhibiting strong nestin co-labelling (Figure 1b-
vi). Nestin, an intermediate ﬁlament protein, is highly expressed in
immature NSPCs and, similar to pCREB, is associated with brain
tumour grade43–45 This suggests that CREB may contribute to
immature tumour cell biology by regulating CREB target genes
involved in tumour cell growth and suppression of differentiation/
promotion of immaturity; this is supported by studies showing
that PI3K regulation of CREB is crucial for NSPC function.46 Our
data also shows that less aggressive GBM tumour subtypes,
known to be associated with better survival, express lower levels
of activated CREB. Giant cell GBM and oligodendroglial regions in
GBM tissue show low to almost no pCREB labelling in most tumour
cells (Figures 1b-iv and -v). It may be that pCREB is a biomarker
associated with GBM malignancy and may also actively promote
malignant properties in the more aggressive types of brain cancer.
Figure 6. Selective dependence of cyclin expression on CREB is
determined by the PI3K pathway and tumour-suppressor PTEN
status in glioma cells. (a, b) T98G and U118 cells were treated with
either scramble or siCREB for 24 h before exposure to serum-free or
serum conditions for 12 h. Cell lysate was then analysed for markers
of PI3K activation. (c) U118 cells were treated with either LY294002,
siCREB or both, and cell lysate was then immunoblotted for cyclin
B1, cyclin D1 and PCNA expression changes. All western blottings
were performed at least three times, and where applicable, total
CREB and AKT were imaged, and then membranes were stripped
and reprobed for pCREB and pAKT detection.
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These putative roles of CREB relate to its position in a complex
signalling network where CREB sits at a convergence point of
multiple oncogenic signalling pathways and is activated by
multiple factors, including the PI3K and MAPK pathways which
are essential contributors to the cancer phenotype. As such, CREB
activation may be reﬂective of oncogenic pathway activation. Use
of the PI3K inhibitor LY294002 and MAPK inhibitor U0126 to
dissect the contribution of these core pathways established a
causal relationship between CREB activation and the PI3K and
MAPK pathways; however, our data also demonstrate that CREB is
activated by multiple pathways in GBM and that these pathways
vary between GBM cell lines (Figures 3b and c). The regulation of
CREB by the PI3K and MAPK pathways appears to be complex and
there is some redundancy in this regulation. Furthermore, CREB is
able to regulate cell proliferation (Figure 4), an important
characteristic of GBM cells to which multiple pathways are able
to contribute.47–49 Taken together, our data suggest that
disruption of oncogenic functions regulated by the PI3K and
MAPK pathways in GBM may be achieved by direct targeting of
CREB rather than the redundant signalling pathways.
One mechanism by which CREB regulates proliferation is via
modulation of the cell cycle, a previously reported role conserved
across multiple cancer and non-cancer cell types.28,50,51
Knockdown of CREB in GBM cell lines T98G and U118 resulted
in attenuation of the cell cycle however the effect on cell cycle
progression was much greater in T98G than U118. The sensitivity
to CREB knockdown differed in the two cells tested, with CREB loss
having a greater effect on cyclin expression in T98G cells
compared with U118 (Figures 5a and b). Cyclin D1 exhibited
robust CREB dependence in both cell lines, whereas CREB
knockdown reduced expression of cyclin B1 and PCNA in T98G
but not in U118 cells (Figures 5c and d). Cyclin D1, cyclin B1 and
PCNA are known markers of poor survival in a multitude of
cancers, such as hepatocellular carcinoma,52 anorectal malignant
melanoma53 epithelial ovarian carcinoma54 and breast cancer.55
Differences observed in the regulation of cell cycle genes by
CREB are likely due to differences in the genetic background of
GBM where PTEN status was most notable in the GBM cell lines
tested (T98GPTENþ , U118PTEN ). The presence or absence of PTEN
can inﬂuence many cellular responses, including proliferation,
with PTEN not only acting as a negative regulator of the canonical
PI3K pathway but inﬂuencing many other PI3K-independent
effects, including roles in cell cycle and DNA integrity.56
Mechanistically, a difference in PTEN status likely explains the
ability for CREB to differentially regulate AKT activity in T98G and
U118 (Figures 6a and b). A feedback loop involving CREB and AKT
may occur through direct CREB-dependent regulation of insulin
receptor substrate 2 (IRS1/2) expression, adaptor proteins down-
stream of IGFR/IR which directly associates with the p85 subunit of
PI3K to activate the PI3K/AKT pathway.57 In the presence of PTEN,
the activation of the PI3K pathway is antagonized, resulting in the
upregulation of IR/IGFR/IRS1/IRS58 in an attempt to maintain AKT
activation. Importantly, CREB has been shown to regulate the
expression of IRS components,59 suggesting a mechanism by
which CREB is able to regulate the activity of AKT. In T98G cells,
the presence of PTEN would inhibit the phosphorylation of IRS1,
while the knockdown of CREB would cause loss of IRS2, leading to
the sustained downregulation of PI3K pathway (Figure 6a). By
contrast, U118 cells that are PTEN null would have no PTEN-
dependent inhibitory inﬂuence on IRS1, thus allowing a serum-
dependent increase in PI3K activity (Figure 6b). In line with this,
the consequence of CREB loss on cell cycle progression and
regulation of cell cycle genes cyclin B1 and PCNA was dependent
on the regulation of PI3K by CREB in a PTEN-dependent manner.
Importantly, co-inhibition of CREB and PI3K activity was necessary
for the downregulation of cyclin B1 and PCNA (Figure 6c),
highlighting the key role for CREB in promoting cell proliferation,
even when the PI3K pathway is inhibited. This has considerable
therapeutic signiﬁcance, as redundancy in oncogenic signalling
networks is a major mechanism by which the clinical impact of
targeted therapies is negated. Indeed, recent reports have
demonstrated that CREB has a major role mediating resistance to
targeted therapies in melanoma,16 which when considered with the
data presented here, highlights the need for further investigation of
CREB and PI3K pathway target genes in tumour cells.
Overall, this study shows that pCREB is a marker of glioma grade
and that CREB activation in GBM cells appears to modulate GBM
tumour cell proliferation through the integration of signals from
PI3K and MAPK pathways (Figure 7). We also show that CREB acts
as a master transcriptional regulator of cyclin D1 in GBM. This
observation is consistent with the spectrum of tumour cell types
where CREB has been shown to regulate cyclin D1 expression,
including malignant T-cells60 gastric cancer cells,61 breast cancer
cells,62 embryonic carcinoma cells63 and prostate cancer cells.
Furthermore, we establish that CREB may be part of a complex
signalling feedback loop modulating the expression of cell cycle
factors. Given the roles CREB has in regulating GBM cell
proliferation and the convergence of multiple redundant cancer
signalling pathways upon CREB, the use of anti-tumour
therapeutic approaches incorporating CREB inhibitors would be
expected to provide more effective anti-tumour responses and
Figure 7. CREB-dependent cell cycle factor expression signalling
network in GBM tumour cells. CREB lies downstream of both the
PI3K and MAPK pathways and modulates cell cycle factor expres-
sion. Cyclin D1 is completely dependent on CREB activity while
cyclin B1 and PCNA appear to require activation of both CREB and
non-CREB mechanisms. The width of the arrow indicates the relative
strength of the signal. The broken arrows pointing from CREB to AKT
indicates the putative CREB-dependent regulation of the PI3K
pathway.
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may bypass the inherent redundancy and associated drug
resistance that promote tumour cell proliferation.
MATERIALS AND METHODS
Cell culture and treatments
Human GBM cell lines (T98G, LN18 and U118) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were
maintained at 37 1C and 5% CO2 in complete media (Dulbecco’s Modiﬁed
Eagle Medium (DMEM) F12þGlutaMAX (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (Fisher Biotech, Wembley, WA,
Australia) and penicillin/streptomycin (Invitrogen) diluted to 50 units/ml of
penicillin and 50mg/ml of streptomycin. Cells were synchronized before
treatment with serum and/or inhibitors by serum starvation for 24 h.
Inhibitor experiments were performed on serum-starved cells using 25 mM
of LY294002 (Genesearch) and/or U0126 (Genesearch, Danvers, MA, USA)
or the equivalent concentration of dimethyl sulphoxide. Cells were
exposed to treatments for 30min before the addition of serum and then
harvested as necessary.
siRNA transfection
Twenty picomolar CREB1-speciﬁc siRNA or scramble siRNA (Santa Cruz,
Dallas, TX, USA) was incubated with 2 ml/ml Lipofectamine RNAiMax
(Invitrogen) in unsupplemented DMEM F12 for 20min at 37 1C to allow
complex formation. Cells were incubated with siRNAs overnight at 37 1C
before washing in phosphate-buffered saline (PBS) and culturing in
complete media (as above).
MTT and FACS analysis
Cell lines were transfected with CREB siRNA or scramble siRNA and then
plated onto 96-well dishes in complete media the next day. Cell growth
was determined every 24 h by incubation with MTT reagent (Invitrogen)
at 1.2mM ﬁnal concentration, for 4 h before lysis in MTT lysis buffer
(isopropanol, 1% Triton-X, 1 drop glacial HCl/50ml). Absorbance at 570 nm
was then measured using a Wallac 1420 VICTOR2 plate reader (GMI,
Ramsey, MN, USA).
Cell cycle and AnnexinV analysis was performed on siRNA-transfected
cells using the MUSE cell analyser (Millipore, Billerica, MA, USA). For
AnnexinV experiments, cells were harvested 48 h after transfection,
resuspended in 100ml complete media and 100ml AnnexinV buffer
solution (Millipore), incubated for 15min at room temperature and then
analysed on the MUSE. For cell cycle analysis, siRNA-transfected cells were
serum starved for 24 h to synchronize cells before the addition of complete
media. Twenty-four hours after the addition of complete media, cells were
harvested and then ﬁxed in ice-cold 80% ethanol overnight. Cells were
then washed and incubated with cell cycle assay buffer (Millipore) for
30min before being analysed on a MUSE cell analyser (Millipore).
Protein extraction and western blotting
Total cellular protein was extracted using RIPA buffer (150mM sodium
chloride, 1% Triton-X, 0.5% sodium deoxycholate, 50mM Tris, pH 8.0)
supplemented with Pierce complete protease and phosphatase inhibitor
tablet (Pierce, Rockford, IL, USA) and then protein quantiﬁed using a BCA
protein assay kit (Pierce). In all, 15–20mg of protein was run on a 10%
polyacrylamide gel by electrophoresis and then transferred onto a
polyvinylidene diﬂuoride membrane (Millipore) before being blocked in
1% Tween-20 Tris-buffered saline pH 6.8 (TBS-T) supplemented with 2%
skim milk. Membranes were probed for speciﬁc proteins using antibodies
as listed below.
Immunohistochemistry
Fixed (4% buffered paraformaldehyde) parafﬁn-embedded tissue was used
to section at 7 mm and then dewaxed with ethanol and histolene.
Immunohistochemical labelling was performed using antibodies as listed
below, with overnight incubation of primary antibodies at 4 1C, followed by
1h incubation of secondary antibodies and solutions for colour develop-
ment provided in a VectoLabs Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA) used according to the manufacturer’s instructions.
Double labelling immunohistochemistry was performed sequentially, each
primary antibody being individually incubated and developed.
Quantitative RT–PCR (qRT–PCR)
Synchronized cells were treated with either scrambled (control) or CREB-
speciﬁc siRNA and then treated with serum for 24 h. Cellular RNA was
harvested by the addition of 300ml of Trizol (Ambion, Foster City, CA, USA)
directly to the plate before addition of 100ml of chloroform (Sigma, St
Louis, MO, USA) and subsequent centrifugation for 15min at 12 000 r.p.m.
for phase separation. The upper RNA phase was collected before being
passed through a NucleoSpin RNA Clean-up XS column (Macherey-Nagel,
D-52313, Du¨ren, Germany). Eight hundred nanograms of RNA was reverse
transcribed using a Superscript III ﬁrst-strand reverse transfection kit
(Invitrogen) and then ampliﬁed with primers speciﬁc to CCND1 (Forward-
50-GATCAAGTGTGACCCGGACTG-30 ; Reverse-50-CCTTGGGGTCCATGTTCT
GC-30), CCNB1 (Forward-50-TGGTGAATGGACACCAACTC-30 ; Reverse-50-TTC
TTAGCCAGGTGCTGCAT-30) or PCNA (Forward-50-GCCCTGGTTCTGGAGGT
AAC-30 ; Reverse-50-TAGCTGGTTTCGGCTTCAGG-30). Ampliﬁcation was per-
formed on a LightCycler480 (Roche, Basel, Switzerland) using LightCycler
480 SYBR Green I Mastermix (Roche) under the following conditions:
preincubation 50 1C for 2min, 95 1C for 2min, ampliﬁcation at 95 1C for 15 s
and then at 55–65 1C for 30 s.
Immunoﬂuorescence
Cells were cultured on poly-d-lysine and ﬁbronectin-coated glass cover-
slips and then incubated with or without BrdU (3mg/ml) for 4 h before
being ﬁxed in 4% paraformaldehyde (Sigma) for 15min on ice. Cells were
then washed in PBS, and BrdU slides were incubated in HCl (1 N) for
10min. Cells were permeabilized and blocked in staining buffer 1 (DPBS
supplemented with 0.1% triton-X, 10% fetal calf serum) for 1 h before
incubation with primary antibodies overnight at 4 1C. Slides were
then washed 3 in DPBS and then co-labelled with Alexa-Fluor
secondary antibodies (Invitrogen) for 1 h. Slides were washed in PBS
again before a 10-min incubation with 100 ng/ml DAPI solution (Sigma).
Slides were then washed a ﬁnal time in distilled water and then mounted
with Fluorogel aqueous anti-fade media (ProSciTech, Townsville City, QLD,
Australia).
Antibodies used
The antibodies used were CREB (Genesearch no. 9197L), pCREB Serine 133
(Genesearch no. 9197), BrdU (Genesearch no. 5292), pH3 (Genesearch no.
9701S), AKT (Genesearch no. 9272), pAKT Threonine 308 (Genesearch no.
9275S), MAPK (Genesearch no. 9102), pMAPK Threonine 202/Tyrosine
204 (Genesearch no. 9101), PKA-C (Genesearch no. 4782), pPKA-C
Threonine197 (Genesearch no. 4781), Cyclin D1 (Abcam no. ab95281),
Cyclin B1 (Abcam no. ab2949), PCNA (Genesearch no. 2586), and GAPDH
(Genesearch no. 2118S). All primary antibodies were used at 1:2000
dilutions for western blottings and 1:100 for immunoﬂuorescence or
immunohistochemistry. Blots were then developed with enhanced
chemiluminescence reagent (Bio-Rad, Hercules, CA, USA) and imaging
performed on a Microchemi (DNR BioImaging Systems, South San
Francisco, CA, USA).
Statistical analysis
Data are presented as mean±s.e.m. of at least three independent
experiments. P-values were determined using a pairwise two-tailed
Student’s t-test, with Po0.05 considered statistically signiﬁcant.
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